Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where ...

To compile our list of the best German stocks to buy, we first made a list of all German firms that are trading on the NASDAQ ...

ADRs quickly plunged 9% in premarket trading amid a report that the company is preparing to fight back against Halozye ...

The global cellular reprogramming tools market is on an impressive growth trajectory, with a projected valuation of USD 400 ...

Halozyme Therapeutics (HALO) provided an update on its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, ...

智通财经APP获悉，据外媒报道， 奥洛兹美医疗 (HALO.US)首席执行官海伦·托利 (Helen Torley)称，公司计划以现金形式融资20亿欧元 (合21亿美元)收购德国Evotec公司 ...

Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic <a tar ...

圣地亚哥 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) 今日宣布计划以每股11.00欧元的价格收购Evotec SE (NASDAQ: EVO)，这笔全现金交易总价值20亿欧元。此次交易旨在打造一家全球领先的制药服务公司，显著扩大和多元化Halozyme的业务范围和财务前景。 这项拟议收购预计将利用Halozyme现有技术和Evotec的平台，创建一个收 ...

Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...

Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in ...

Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...